SWOG临床试验中的药物相互作用筛查现况调查
该研究向180名SWOG主要临床研究助理发放问卷,调查入组临床试验时药物相互作用(DI)筛查的频率与执行人员。83份问卷至少回答1题,回复率46.1%,完成率40.0%。多数中心(51%)仅在方案排除标准含DI时于资格评估阶段筛查,药师「始终」参与筛查的中心仅17%,DI筛查未系统化开展。
要点
- 51%中心仅在方案排除标准含DI时于资格评估阶段筛查。
- 临床研究协调员(56%)与研究护士(45%)是DI筛查主要执行者。
- 17%中心药师「始终」参与资格评估期DI筛查,3-6%中心无药师可及。
核心结论
- 调查显示SWOG临床试验中DI筛查未系统化开展,且药师主导的DI筛查并非受调查中心的现行实践。
研究设计与样本
- 向180名SWOG主要临床研究助理发放电子邮件调查问卷,了解其中心在受试者筛查和入组时DI评估的频率与参与人员,采用描述性统计。
主要发现
- 83份问卷至少回答1题,总体回复率46.1%;至少72份完成问卷,完成率40.0%。
- 51%中心报告DI筛查仅在资格评估且方案排除标准含DI时进行。
- 资格评估期药师「始终」参与DI筛查的中心占17%;临床研究协调员(56%)和研究护士(45%)为DI筛查主要执行人员。
- 3-6%中心报告无药师可及;不足10%中心「始终」使用药物信息服务、网站、资源或文献检索,但超过20%中心「经常」或「有时」使用多种工具。
关键数值与推荐
- 回复率46.1%(83/180至少回答1题),完成率40.0%(至少72份完成问卷)。
- 51%中心仅在方案排除标准含DI时于资格评估阶段筛查DI。
- 17%中心药师「始终」参与资格评估期DI筛查;56%由临床研究协调员、45%由研究护士执行DI筛查。
- 3-6%中心无药师可及;不足10%中心「始终」使用药物信息工具,超过20%中心「经常」或「有时」使用。
临床怎么用
- 在临床试验资格评估中应系统纳入DI筛查,而非仅依赖方案排除标准触发。
- 鉴于DI筛查多由研究协调员或研究护士执行,应加强其药物相互作用培训并建立药师支持路径。
- 针对无药师可及的中心,应提供药物信息工具与药学服务资源以支持DI评估。
局限性
- 调查仅覆盖SWOG中心,结果外推至其他临床试验网络需谨慎。
- 问卷回复率46.1%、完成率40.0%,存在无应答偏倚可能。
- 为描述性调查研究,未报告DI筛查与临床结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The frequency and process for drug interaction (DI) screening at sites enrolling patients into SWOG clinical trials were studied. METHODS: Survey invitations were e-mailed to 180 SWOG head clinical research associates to determine the frequency of and personnel involved in DI assessment in subjects who were screened for and enrolled in clinical trials at their sites. Descriptive statistics were performed to evaluate the data. RESULTS: A total of 83 surveys recorded a response to at least 1 question, yielding an overall response rate of 46.1%. At least 72 completed surveys were submitted, for a completion rate of 40.0%. The majority of sites (51%) reported that DI screening only occurred during eligibility assessment when a DI was included in the protocol exclusion criteria. The pharmacist was "always" involved in DI screening during eligibility assessment at 17% of sites. Clinical research coordinators (56%) and research nurses (45%) were the predominant personnel who performed DI screening to assess eligibility for trial enrollment. A subset of sites (3-6%) reported not having access to a pharmacist. Fewer than 10% of sites reported that they "always" use drug information services, websites, resources, or literature searches, though many tools were used "often" or "sometimes" by more than 20% of sites. CONCLUSION: A survey revealed that DI screening was not being systematically conducted within SWOG clinical trials. When DI screening did occur, it was primarily conducted by clinical research coordinators or study nurses. Pharmacist-led DI screening was not the current practice within SWOG sites surveyed and was precluded by a lack of pharmacists' availability or involvement.
引用
- Hertz DL, Siden R, Modlin J, et al. Drug interaction screening in SWOG clinical trials. Am J Health Syst Pharm. 2018. PMID: 29748299. doi:10.2146/ajhp170449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。